"In addition to new orders, we began delivering our 208-inch extended wheelbase W56 step vans in April to a national customer through our partner, Revolv. We also secured a purchase order from a municipal fleet in Washington for two W4 CC trucks through one of our certified dealers, The Truck Shop. Expanding our product line remains a top engineering priority, and the development of the 140 kWh version of the W56 is progressing on schedule. We continue to receive strong feedback from potential customers at ...

Summary of Roivant Sciences (ROIV) Conference Call Company Overview - **Company**: Roivant Sciences (ROIV) - **Event**: BofA Annual Healthcare Conference - **Date**: May 14, 2025 Key Points Immunovant and Clinical Focus - Roivant is transitioning its focus to IVD 1402, a next-generation program, after late-stage studies in betoclimab for MG and CIDP [8] - Eric Vanker has taken over as CEO of Immunovant, emphasizing patient enrollment in Graves' disease as the top priority [9] - Graves' disease is identified as a unique opportunity with a large patient population and high unmet need [11] Market Dynamics and Patient Population - Approximately 350,000 Graves' patients in the US are refractory to current treatments, primarily methimazole [25] - The current treatment landscape for Graves' disease has not seen a novel drug in 70 years, creating a significant opportunity for Roivant [29] - The company aims to address the operational challenges of enrolling patients in clinical trials due to the lack of recent novel therapies [30] Value Proposition of Therapy - The therapy aims to improve patient quality of life by reducing reliance on methimazole and potentially achieving drug-free remission [36] - Evidence from phase two data shows that 76% of patients on high doses achieved T3 and T4 normalization, with 56% able to discontinue anti-thyroid drugs [46] - The company is also exploring the potential to reduce the onset of Thyroid Eye Disease (TED) in hyperthyroid patients with proptosis [38] Regulatory and Clinical Trial Insights - The FDA has shown enthusiasm for new therapies in Graves' disease, indicating a supportive regulatory environment [51] - The first GRAVE study will treat patients for six months before randomization to assess remission rates [41] - The company is optimistic about the potential for accelerated approval based on positive clinical outcomes [85] Myasthenia Gravis (MG) and CIDP Challenges - Roivant acknowledges the challenges of entering the MG market, dominated by Argenx, and recognizes the need for deeper clinical data to compete effectively [58] - The company aims to shift the focus in MG from treatment response to deeper remission endpoints, which could favor their drug's profile [61] Dermatomyositis and Other Programs - Roivant is preparing for a phase three trial in dermatomyositis, with expectations for regulatory approval based on statistical significance [78] - The company is also developing a pulmonary hypertension program, with data expected in the second half of next year [87] Legal Matters - Roivant is involved in litigation regarding intellectual property related to lipid nanoparticles used in COVID vaccines, with a jury trial scheduled for September 2025 [90] - Potential damages from the case could be substantial, given the scale of global COVID vaccine sales [93] Additional Insights - The company is focused on executing its current indications before exploring new opportunities, indicating a disciplined approach to R&D investment [66] - Roivant is evaluating its pipeline continuously and may announce new indications as they progress [66] This summary encapsulates the key discussions and insights from the Roivant Sciences conference call, highlighting the company's strategic focus, market opportunities, and ongoing challenges in the biopharmaceutical landscape.

Core Viewpoint - FibroBiologics is advancing its clinical-stage biotechnology efforts with plans to initiate a Phase 1/2 clinical trial for its fibroblast-based product candidate, CYWC628, aimed at treating diabetic foot ulcers in Australia by the third quarter of 2025 [1][4]. Recent Highlights - The company completed the CYWC628 master cell bank with Charles River, establishing a foundation for the upcoming clinical trial [4]. - A new patent was filed to enhance mitochondrial activity using the fibroblast platform, indicating a strategic move to strengthen competitive advantage [4]. - FibroBiologics presented at several investor and scientific conferences, enhancing visibility and interest in its platform [6]. Upcoming Milestones - The Phase 1/2 clinical trial for CYWC628 is set to begin in the third quarter of 2025, with completion expected in the first quarter of 2026 [6]. - Pre-clinical IND-enabling studies for the treatment of psoriasis with the fibroblast spheroid product candidate, CYPS317, are anticipated to be completed by the end of 2025 [6]. Financial Highlights - For the quarter ended March 31, 2025, research and development expenses were approximately $1.8 million, up from $1.0 million in the same period in 2024, primarily due to increased drug product expenses and hiring [7]. - General and administrative expenses rose to approximately $2.8 million from $2.5 million year-over-year, mainly due to additional personnel costs [8]. - The net loss for the quarter was approximately $5.0 million, a decrease from $8.5 million in the same period in 2024, attributed to changes in the fair value of the warrant liability [12].

Core Viewpoint - RTX Corporation's unit, Raytheon, has secured a significant $2.13 billion modification contract for the Standard Missile-3 (SM-3) Block missile, indicating strong demand for missile defense systems amid increasing global military spending [1][2]. Summary by Sections Contract Details - The contract involves management, materials, and services for sustaining engineering and product support of SM-3 missile variants for U.S. and Foreign Military Sales partners, projected to be completed by October 29, 2029 [2]. - This modification raises the total contract value from $1.20 billion to $3.33 billion, reflecting the growing importance of missile defense systems [2]. Market Trends - Global military spending on advanced arms, including missiles, is on the rise, benefiting RTX as a key manufacturer of missile systems [3]. - The SM-3 interceptor is a critical defensive weapon for the U.S. Navy, capable of targeting and destroying short to intermediate-range ballistic missiles, showcasing its advanced technology and effectiveness [4]. Performance and Demand - The SM-3 program has achieved over 30 successful space intercepts, with more than 400 interceptors delivered to the U.S. and Japanese navies, indicating strong market demand [5]. - Rising military conflicts and national security concerns are driving nations to invest in missile defense systems, with a projected compound annual growth rate of 5% for the global missiles and missile defense system market from 2025 to 2030 [6]. Competitive Landscape - RTX's product portfolio includes several combat-proven missiles, positioning the company favorably in the expanding missile market [7]. - Other defense companies like Northrop Grumman, Boeing, and Lockheed Martin are also expected to benefit from the growing missile defense market, each with their own product offerings and growth projections [8][10][11]. Stock Performance - RTX shares have increased by 9.3% over the past six months, outperforming the industry average growth of 8.6% [15].

MONTRÉAL, May 14, 2025 (GLOBE NEWSWIRE) -- Bombardier Inc. (“Bombardier”) today announced that it has launched an offering of US$500 million aggregate principal amount of new Senior Notes due 2033 (the “New Notes”). Bombardier intends to use the proceeds of the offering of the New Notes, together with cash on hand, (i) to fund the repayment and/or retirement of outstanding indebtedness, including the redemption of US$500 million aggregate principal amount of its outstanding 7.875% Senior Notes due 2027 (the ...

Core Viewpoint - Ignitis Group has published its Strategic Plan for 2025–2028, focusing on creating a 100% green and secure energy ecosystem for future generations [1] Group's Green Capacities Portfolio - The Group aims to expand its Green Capacities Portfolio to 4–5 GW by 2030, enhancing energy security and contributing to surplus green energy production [2] - The target is to double installed Green Capacities to 2.6–3.0 GW by 2028, up from 1.4 GW in 2024, with a current total of 8.4 GW, including 3.1 GW of Secured Capacity [3] Electricity Supply and EV Charging Network - The Group plans to increase electricity supply from 6.7 TWh in 2024 to 9.0–11.0 TWh by 2028, while also developing a leading EV fast-charging network in the Baltics [4] Financial Investments and Targets - Planned investments for 2025–2028 range from EUR 3.0–4.0 billion, with 85–90% aligned with EU Taxonomy [6] - Approximately 59% of these investments (EUR 1.7–2.4 billion) will focus on developing Green Capacities, while 36% (EUR 1.2–1.3 billion) will be directed towards electricity distribution network expansion [7] Financial Performance Expectations - Investments are expected to generate EUR 600–680 million in Adjusted EBITDA by 2028, an increase from EUR 527.9 million in 2024, with a target of 70–75% sustainable Adjusted EBITDA share [8] - The average Adjusted ROCE is projected to be between 6.5–7.5% during 2025–2028 [8] Credit Rating and Dividend Policy - The Group aims to maintain a credit rating of 'BBB' or above, with a commitment to a minimum of 3% annual dividend growth, resulting in a projected dividend yield of 6.4%–7.0% for the 2025–2028 period [9] Sustainability Goals - The Group targets net zero emissions by 2040–2050, with a focus on reducing carbon intensity of Scope 1 & 2 GHG emissions to 190 g CO2-eq/kWh by 2028, representing a 5% reduction from 2024 [10]

CALGARY, Alberta, May 13, 2025 (GLOBE NEWSWIRE) -- Freehold Royalties Ltd. (Freehold or the Company) (TSX:FRU) announces first quarter results for the period ended March 31, 2025. First Quarter 2025 Highlights $91 million in revenue;$68 million in funds from operations ($0.42/share) (1)(3);$44 million in dividends paid ($0.27/share)(2);10,635 bbls/d of total liquids production, an 8% increase from previous quarter driven by continued execution of our U.S. expansion strategy and heavy oil growth in Canada;1 ...

Core Points - Brookfield Infrastructure Partners L.P. announced the issuance of $250 million in Fixed-to-Fixed Reset Rate Subordinated Notes due September 1, 2055, with an initial interest rate of 5.598% until September 1, 2030, and subsequent resets every five years [1][2] - The net proceeds from the offering will be used for general corporate purposes, including repayment of outstanding debt [1] - The Notes will be issued by Brookfield Infrastructure Finance ULC, a wholly-owned subsidiary, and are guaranteed on a subordinated basis by Brookfield Infrastructure and certain subsidiaries [2][3] Company Overview - Brookfield Infrastructure is a leading global infrastructure company that operates high-quality, long-life assets in utilities, transport, midstream, and data sectors across the Americas, Asia Pacific, and Europe [7] - The company focuses on assets with contracted and regulated revenues that generate predictable and stable cash flows [7] - Brookfield Infrastructure is the flagship listed infrastructure company of Brookfield Asset Management, which manages over $1 trillion in assets [8]

Company Update 1Q 2025 1 1 Forward-looking statements ABOUT THIS PRESENTATION This presentation is provided by Oklo Inc. ("Oklo") for informational purposes only. The information contained herein does not purport to be all inclusive and no representations or warranties, express or implied, are given in, or in respect of, this presentation. To the fullest extent permitted by law, in no circumstances will Oklo or any of its subsidiaries, interest holders, affiliates, representatives, partners, directors, offi ...

WARRENVILLE, Ill., May 13, 2025 (GLOBE NEWSWIRE) -- Fuel Tech, Inc. (NASDAQ: FTEK), a technology company using advanced engineering processes to provide emissions control systems and water treatment technologies in utility and industrial applications, today announced that Chairman and Chief Executive Officer Vince Arnone is scheduled to present and host one-on-one meetings with investors at the Sidoti Micro-Cap Virtual Investor Conference, taking place on May 21-22, 2025. Presentation Date & Time: May 22, 2 ...